Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neuronetics' NeuroStar Depression Therapy Not Backed By Data - Blues

This article was originally published in The Gray Sheet

Executive Summary

Existing evidence does not support the long-term efficacy of Neuronetics' NeuroStar transcranial magnetic stimulation therapy for drug-resistant depression, according to a recent 1assessment by the Blue Cross and Blue Shield Association Technology Evaluation Center

You may also be interested in...



Neuronetics Plans Expanded Marketing For Transcranial Magnetic Stimulation Depression Therapy

Despite a recent negative Blue Cross Blue Shield technology assessment, Neuronetics is moving ahead with plans to expand sales and marketing efforts for its NeuroStar transcranial magnetic stimulation therapy for drug-resistant depression.

Neuronetics Plans Expanded Marketing For Transcranial Magnetic Stimulation Depression Therapy

Despite a recent negative Blue Cross Blue Shield technology assessment, Neuronetics is moving ahead with plans to expand sales and marketing efforts for its NeuroStar transcranial magnetic stimulation therapy for drug-resistant depression.

FDA Neuro Devices Panel Examines Suicide Risk In Depression Trial Subjects

Clinical trials of devices for depression do not readily lend themselves to hard-and-fast rules on when the rate of patient suicides might require a trial to be halted, according to FDA’s neurological devices panel.

Related Content

Topics

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel